N Hugen1, C J H van de Velde2, J H W de Wilt3, I D Nagtegaal4. 1. Department of Surgery, Radboud university medical center, Nijmegen. Electronic address: niek.hugen@radboudumc.nl. 2. Department of Surgery, Leiden University Medical Center, Leiden. 3. Department of Surgery, Radboud university medical center, Nijmegen. 4. Department of Pathology, Radboud university medical center, Nijmegen, The Netherlands.
Abstract
BACKGROUND: Clinical studies regarding colorectal cancer (CRC) have suggested differences in metastatic patterns between mucinous adenocarcinoma (MC), signet-ring cell carcinoma (SRCC) and the more common adenocarcinoma (AC). The current study systematically evaluates metastatic patterns of different histological subtypes in CRC patients and analyzes metastatic disease upon primary tumor localization. PATIENTS AND METHODS: A nationwide retrospective review of pathological records of 5817 patients diagnosed with CRC who underwent an autopsy between 1991 and 2010 was performed. Patients were selected from the Dutch pathology registry (PALGA). To substantiate clinical relevance, metastatic patterns were compared with the prospective randomized multicenter Total Mesorectal Excision (TME) trial, which investigated efficacy of preoperative radiotherapy in rectal cancer patients. RESULTS: In the autopsy study, 1675 patients had metastatic disease. MC and SRCC patients more frequently had metastatic disease (33.9% and 61.2% versus 27.6%; P < 0.0001) and had metastases at multiple sites more often compared with AC patients (58.6% and 70.7% versus 49.9%; P = 0.001). AC predominantly metastasized to the liver, and MC and SRCC more frequently had peritoneal metastases. Metastatic patterns were also related to the primary tumor site, with a high rate of abdominal metastases in colon cancer patients, whereas rectal cancer patients more often had metastases at extra-abdominal sites. Results from the TME trial confirmed findings in rectal cancer patients from the autopsy study. CONCLUSION: There are profound differences in metastatic patterns between histological subtypes and the localization of the primary tumor in CRC. Findings from this study should encourage to take these factors into account for follow-up strategies and future studies.
BACKGROUND: Clinical studies regarding colorectal cancer (CRC) have suggested differences in metastatic patterns between mucinous adenocarcinoma (MC), signet-ring cell carcinoma (SRCC) and the more common adenocarcinoma (AC). The current study systematically evaluates metastatic patterns of different histological subtypes in CRCpatients and analyzes metastatic disease upon primary tumor localization. PATIENTS AND METHODS: A nationwide retrospective review of pathological records of 5817 patients diagnosed with CRC who underwent an autopsy between 1991 and 2010 was performed. Patients were selected from the Dutch pathology registry (PALGA). To substantiate clinical relevance, metastatic patterns were compared with the prospective randomized multicenter Total Mesorectal Excision (TME) trial, which investigated efficacy of preoperative radiotherapy in rectal cancerpatients. RESULTS: In the autopsy study, 1675 patients had metastatic disease. MC and SRCC patients more frequently had metastatic disease (33.9% and 61.2% versus 27.6%; P < 0.0001) and had metastases at multiple sites more often compared with AC patients (58.6% and 70.7% versus 49.9%; P = 0.001). AC predominantly metastasized to the liver, and MC and SRCC more frequently had peritoneal metastases. Metastatic patterns were also related to the primary tumor site, with a high rate of abdominal metastases in colon cancerpatients, whereas rectal cancerpatients more often had metastases at extra-abdominal sites. Results from the TME trial confirmed findings in rectal cancerpatients from the autopsy study. CONCLUSION: There are profound differences in metastatic patterns between histological subtypes and the localization of the primary tumor in CRC. Findings from this study should encourage to take these factors into account for follow-up strategies and future studies.
Authors: N Hugen; R H A Verhoeven; S A Radema; I H J T de Hingh; J F M Pruijt; I D Nagtegaal; V E P P Lemmens; J H W de Wilt Journal: Ann Oncol Date: 2013-09-20 Impact factor: 32.976
Authors: Teppei Morikawa; Aya Kuchiba; Zhi Rong Qian; Mari Mino-Kenudson; Jason L Hornick; Mai Yamauchi; Yu Imamura; Xiaoyun Liao; Reiko Nishihara; Jeffrey A Meyerhardt; Charles S Fuchs; Shuji Ogino Journal: Ann Surg Oncol Date: 2011-12-22 Impact factor: 5.344
Authors: Marko Kornmann; Ludger Staib; Thomas Wiegel; Martina Kron; Doris Henne-Bruns; Karl-Heinrich Link; Andrea Formentini Journal: Clin Colorectal Cancer Date: 2012-10-27 Impact factor: 4.481
Authors: V Catalano; F Loupakis; F Graziano; U Torresi; R Bisonni; D Mari; L Fornaro; A M Baldelli; P Giordani; D Rossi; P Alessandroni; L Giustini; R R Silva; A Falcone; S D'Emidio; S L Fedeli Journal: Br J Cancer Date: 2009-03-03 Impact factor: 7.640
Authors: M Casparie; A T M G Tiebosch; G Burger; H Blauwgeers; A van de Pol; J H J M van Krieken; G A Meijer Journal: Cell Oncol Date: 2007 Impact factor: 6.730
Authors: Derek Reichel; Louis T Curtis; Elizabeth Ehlman; B Mark Evers; Piotr Rychahou; Hermann B Frieboes; Younsoo Bae Journal: Pharm Res Date: 2017-08-24 Impact factor: 4.200
Authors: Linda M Pak; Nancy E Kemeny; Marinela Capanu; Joanne F Chou; Taryn Boucher; Andrea Cercek; Vinod P Balachandran; T Peter Kingham; Peter J Allen; Ronald P DeMatteo; William R Jarnagin; Michael I D'Angelica Journal: J Surg Oncol Date: 2017-11-22 Impact factor: 3.454
Authors: Jamaica R Robinson; Polly A Newcomb; Sheetal Hardikar; Stacey A Cohen; Amanda I Phipps Journal: Cancer Epidemiol Date: 2017-04-21 Impact factor: 2.984
Authors: Niek Hugen; Gina Brown; Robert Glynne-Jones; Johannes H W de Wilt; Iris D Nagtegaal Journal: Nat Rev Clin Oncol Date: 2015-09-01 Impact factor: 66.675